Key Highlights• Ondine Biomedical is in focus on 11 November 2026 after the company highlighted analysis estimating an average C$2,056 incremental cost per cardiac surgery associated with surgical-site infections and an estimated 10% loss of surgical capacity.• Investors are watching the next milestone, financial …
BioPharma Credit has entered into a senior securedLoanagreement with CorMedix under which the investment trust can provide up to US$50 million. A parallel vehicle can invest up to a further US$100 million, creating a totalFacilityof up to US$150 million across two tranches. CorMedix is …
Frontier IP has highlighted a £500,000 grant awarded to portfolio company TheVaccineGroup and the Animal and Plant Health Agency for bovine respiratory syncytial virus vaccine research. The project builds on earlier trials in calves and is intended to determine the minimum effective dose and …
Physiomics has moved into focus after 14 million new ordinary shares were scheduled for admission to AIM at 0.50 pence per share. Following admission, the enlargedShare Capitalis approximately 467.2 million ordinary shares. The company develops computational modelling tools intended to supportDrug Developmentand oncology decision-making.
Renalytix has announced its participation in the Mello2026 investor event on 17 November, with CEO James McCullough scheduled to present the company and its strategy. The company focuses on precision-medicine diagnostics for kidney disease, with its KidneyIntelX platform central to the commercial proposition.
LSE:NFX trades on the Main Market and is associated with the Main Market. ItsMarket Valueis approximately £2.61 million, placing it in the small-cap segment under a broad UK market-cap framework.
Key Highlights• Novacyt is in focus on 11 November 2026 after the company has continued to expand the Yourgene DPYD assayFranchiseafter its IVDR-certified commercial launch in Europe, with international market access remaining a key growth theme.• Investors are watching the next milestone, financial implications …
Key Highlights• Thalia Therapeutics is in focus on 11 November 2026 after the company has been advancing its RNA gene-silencing cardiovascular programme while continuing development of its broader RNA therapeutics pipeline.• Investors are watching the next milestone, financial implications and execution for LSE:THAT.Why Is …
Avacta is a UK biotechnology company developing cancer therapies built on its pre|CISION platform. The platform attaches a cancer drug to a peptide that is cleaved by fibroblast activation protein, an enzyme found in high concentrations in the tissue surrounding many solid tumours. The …
The company bought back 15,625,000 ordinary shares at 80p each, about 3.7% of its issued capital, and cancelled them. Following cancellation, the number of shares in issue and total voting rights stands at 405,241,313.